

## **LABELLING**

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING  
HDPE Bottle**

**1. Name of the medicinal product**

[HP025 trade name]\*

Daclatasvir (as dihydrochloride)/Sofosbuvir 60mg/400mg Tablets

**2. Statement of active substance**

Each film-coated tablet contains 60 mg daclatasvir and 400 mg sofosbuvir.

**3. List of excipients**

Contains lactose

See patient information leaflet for further information.

**4. Pharmaceutical form and contents**

Film-coated tablets

28 tablets

**5. Method and route of administration**

Oral use.

Read the patient information leaflet before use.

**6. Special warning that the medicinal product must be stored out of the reach and sight of children**

Keep out of the reach of children.

**7. Other special warning(s), if necessary**

**8. Expiry date**

EXP {MM/YYYY}

**9. Special storage conditions**

Do not store above 30°C. Store in the original container.

**10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate**

**11. Name and address of the supplier**

Mylan Laboratories Limited

Plot No.564/A/22, Road No. 92, Jubilee Hills

---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Hyderabad – 500096  
Telangana  
India

**12. WHO Reference Number (Prequalification Programme)**

HP025

**13. Manufacturer's batch number**

<Batch> <Lot> {number}

**14. (Advice on) General classification for supply**

Medicinal product subject to medical prescription.

**15. Instructions on use**